The DTNBP1 (Dystrobrevin Binding Protein 1) antibody is a tool used to detect the protein encoded by the *DTNBP1* gene, also known as dysbindin-1. This gene is associated with neurodevelopmental and psychiatric disorders, particularly schizophrenia, as postmortem studies have shown reduced dysbindin-1 expression in brain regions like the hippocampus and prefrontal cortex of affected individuals. Additionally, mutations in *DTNBP1* are linked to Hermansky-Pudlak syndrome type 7. a rare genetic disorder affecting lysosome-related organelles. Dysbindin-1 functions as part of the BLOC-1 (Biogenesis of Lysosome-related Organelles Complex-1), regulating vesicular trafficking, synaptic plasticity, and neurotransmitter release. DTNBP1 antibodies are widely used in research to study the protein's localization, expression levels, and interactions in cellular and animal models. They enable techniques such as Western blotting, immunohistochemistry, and immunofluorescence, helping to clarify dysbindin-1's role in synaptic function and disease mechanisms. These antibodies often target specific isoforms (e.g., dysbindin-1A, -1B, -1C) and are validated for cross-reactivity in humans, mice, and rats. Their application has advanced understanding of how *DTNBP1* disruptions contribute to pathological changes, offering insights into potential therapeutic targets for neuropsychiatric conditions.